vTv Therapeutics Reveals Ongoing Hypoglycemia Challenges for T1D Patients

HIGH POINT, N.C., Oct. 10, 2026 /CourierPR/ -- vTv Therapeutics, a late-stage biopharmaceutical company, announced significant findings at the inaugural Breakthrough T1D Clinical & Research Congress (CRC 2026) in Philadelphia, PA. The company’s Chief Medical Officer, Dr. Thomas Strack, presented research highlighting the ongoing challenges faced by adults with type 1 diabetes (T1D) using automated insulin delivery (AID) systems.

The research, commissioned by vTv Therapeutics and conducted by dQ&A Market Research, Inc., involved 674 adults with T1D, of whom 429 were using AID systems. The study examined the prevalence of hypoglycemia-related burdens among these individuals. Among adult AID system users, 24% reported experiencing frequent Level 2 hypoglycemia, defined as daily, almost daily, or a few moderate hypoglycemic events (<54 mg/dL) in a typical week. Additionally, 12% reported a Level 3 event in the past 12 months, and 17% reported impaired awareness of hypoglycemia, defined as never or rarely noticing or feeling the symptoms of hypoglycemia.

Furthermore, the study found that among those with an A1C level greater than 7%, 49% strongly agreed that they often keep their blood glucose higher to avoid hypoglycemia or that they would target lower glucose levels if not for the risk of hypoglycemia. These findings underscore the ongoing challenges of managing T1D, despite advancements in insulin delivery technology.

Cadisegliatin (TTP399), a novel, oral small-molecule glucokinase activator being investigated by vTv Therapeutics, is being evaluated as a potential first-in-class adjunctive therapy for T1D. In nonclinical studies, cadisegliatin acted selectively on the liver and increased the activity of glucokinase independently of insulin. These studies support clinical investigation of whether cadisegliatin can improve glycemic control through hepatic glucose uptake and glycogen storage. Cadisegliatin has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA).

The company is currently investigating cadisegliatin in a U.S. Phase 3 study for the treatment of T1D. However, it is important to note that the safety and efficacy of cadisegliatin have not been established, and there is no guarantee that this product will receive health authority approval or become commercially available for the use being investigated.